Quick Answer
Tarsus Pharmaceuticals, Inc. reported Research And Development Expense of $64.32 million for the year ending 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +20.5% in Research And Development Expense from 2024 to 2025.
- This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $399.0 thousand | Q1 2020: $1.51 million | Q2 2020: $1.74 million | Q3 2020: $7.99 million | Q1 2021: $16.26 million | Q2 2021: $7.20 million | Q3 2021: $10.21 million | Q1 2022: $12.08 million | Q2 2022: $9.60 million | Q3 2022: $10.91 million | Q1 2023: $12.36 million | Q2 2023: $12.55 million | Q3 2023: $12.11 million | Q1 2024: $12.07 million | Q2 2024: $12.32 million | Q3 2024: $12.13 million | Q1 2025: $14.41 million | Q2 2025: $15.59 million | Q3 2025: $16.28 million.
- Over the full 7 years of available data (2019 to 2025), Tarsus Pharmaceuticals, Inc.'s Research And Development Expense has grown by 1,934.2%.
- Historical annual values: Fiscal year 2025: $64.32 million | Fiscal year 2024: $53.39 million | Fiscal year 2023: $50.31 million | Fiscal year 2022: $42.62 million | Fiscal year 2021: $41.71 million | Fiscal year 2020: $18.83 million | Fiscal year 2019: $3.16 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: